Citations

Clear

1053 citation(s) found for "Andre, F".

HLA haplotypes in primary sclerosing cholangitis patients of admixed and non‐European ancestry
Henriksen, Eva , Viken, Marte K. , Wittig, Michael , Holm, Kristian , Folseraas, Trine , Mucha, Sören , Melum, Espen , Hov, Johannes R. , Lazaridis, K.N., Juran, Brian D., Chazouillères, O., Färkkilâ, Martti , Gotthardt, Daniel , Carbone, Marco , Hirschfield, Gideon M. , Rushbrook, Simon, Goode, Elizabeth C. , Ponsioen, Cyriel Y. , Weersma, Rinse K. , Eksteen, Bertus , Yimam, Kidist, Goldberg, David S. , Yu, Leonard T., Bowlus, Christopher L. , Lie, Benedicte A. , Karlsen, Tom H. , Henriksen, E K K , Viken, M K , Invernizzi, Pietro , Gordon, Stuart C. , Franke, André , Bowlus, Christopher L , Carbone, Marco , Hirschfield, Gideon M , Hov, Johannes R

Mayo Clinic

HLA | July 11, 2017 | Volume: 90 | Issue: 4 | Pages: 228-233

10.1111/tan.13076 | PMID 28695657 Get It

Primary sclerosing cholangitis (PSC) is strongly associated with several human leukocyte antigen (HLA) haplotypes. Due to extensive linkage disequilibrium and multiple polymorphic candidate genes in the HLA complex, identifying the alleles responsible for these associations has proven difficult. We aimed to evaluate whether studying populations of admixed or non‐European descent could help in defining the causative HLA alleles. When assessing haplotypes carrying HLA‐DRB1*13:01 (hypothesized to specifically increase the susceptibility to chronic cholangitis), we observed that every haplotype in the Scandinavian PSC population carried HLA‐DQB1*06:03. In contrast, only 65% of HLA‐DRB1*13:01 haplotypes in an admixed/non‐European PSC population carried this allele, suggesting that further assessments of the PSC‐associated haplotype HLA‐DRB1*13:01‐DQA1*01:03‐DQB1*06:03 in admixed or multi‐ethnic populations could aid in identifying the causative allele.
Correction: The complex genetics of gait speed: genome-wide meta-analysis approach
Ben-Avraham, Dan, Karasik, David , Verghese, Joe , Lunetta, Kathryn L. , Eicher, John D., Vered, Rotem, Deelen, Joris , Arnold, Alice M. , Buchman, Aron S. , Faul, Jessica D. , Nethander, Maria , Fornage, Myriam , Adams, Hieab H.H. , Matteini, Amy M., Callisaya, Michele L. , Smith, Albert V. , Yu, Lei, Jager, Philip L. De , Evans, Denis A., Guðnason, Vilmundur , Hofman, Albert , Pattie, Alison, Knopman, Davis S., Parimi, Neeta, Bandinelli, Stefania , Beekman, Marian , Gutman, Danielle , Sharvit, Lital , Mooijaart, Simon P. , Liewald, David C. , Houwing‐Duistermaat, Jeanine J. , Ohlsson, Claes , Moed, Matthijs, Hernandez, Dena, Thomson, Russell , Tranah, Gregory J. , Weir, David R. , Zhao, Wei , Starr, John M. , Johnson, Andrew D. , Bennett, David A. , Cummings, Steven R. , Deary, Ian J. , Harris, Tamara B., Kardia, Sharon L. R., Mosley, Thomas H. , Srikanth, Velandai , Windham, B. Gwen , Davies, Gail , Evans, Daniel S. , Ferrucci, Luigi , Atzmon, Gil , Bennett, David A. , Turner, Stephen T. , Smith, Jennifer A. , Tanaka, Toshiko , Corley, Janie , Launer, Lenore J. , Verlinden, Vincentius J.A. , Mellström, Dan , Geest, Jos N. van der , Karlsson, Magnus K , McWhirter, Rebekah , Liu, Ching‐Ti , Uitterlinden, André G. , Ikram, M. Arfan , Newman, Anne B. , Walston, Jeremy D , Slagboom, P. Eline , Kiel, Douglas P. , Murabito, Joanne M. , Adams, Hieab H H , Smith, Albert V , Ferrucci, Luigi , Ohlsson, Claes , Srikanth, Velandai K

Mayo Clinic

Aging | July 7, 2017 | Volume: 9 | Issue: 7 | Pages: 1844-1846

10.18632/aging.101260 | PMID 28696945 Get It

The metabolic syndrome alters the miRNA signature of porcine adipose tissue‐derived mesenchymal stem cells
Eirin, Alfonso , Zhu, Xiangyang , Chanana, Pritha , Wijnen, André J. van , Lerman, Lilach O. , Meng, Yu , Tang, Hui Ru , Lerman, Amir , van Wijnen, Andre J , Eirin, Alfonso

Mayo Clinic

Cytometry Part A | July 5, 2017 | Volume: 93 | Issue: 1 | Pages: 93-103

10.1002/cyto.a.23165 | PMID 28678424 Get It

AbstractAutologous transplantation of mesenchymal stem cells (MSCs) is a viable option for the treatment of several diseases. Evidence indicates that MSCs release extracellular vesicles (EVs) and that EVs shuttle miRNAs to damaged parenchymal cells to activate an endogenous repair program. We hypothesize that comorbidities may interfere with the packaging of cargo in MSC‐derived EVs. Therefore, we examined whether metabolic syndrome (MetS) modulates the miRNA content packed within MSC‐derived EVs. MSCs were collected from swine abdominal adipose tissue after 16 weeks of lean or obese diet (n = 7 each). Next‐generation RNA sequencing of miRNAs (miRNA‐seq) was performed to identify miRNAs enriched in MSC‐derived EVs and their predicted target genes. Functional pathway analysis of the top 50 target genes of the top 4 miRNAs enriched in each group was performed using gene ontology analysis. Lean‐ and MetS‐EVs were enriched in, respectively, 14 and 8 distinct miRNAs. Target genes of miRNAs enriched in MetS‐EVs were implicated in the development of MetS and its complications, including diabetes‐related pathways, validated transcriptional targets of AP1 family members Fra1 and Fra2, Class A/1 (Rhodopsin‐like receptors), and Peptide ligand‐binding receptors. In contrast, miRNAs enriched in Lean EVs target primarily EphrinA‐EPHA and the Rho family of GTPases. MetS alters the miRNA content of EVs derived from porcine adipose tissue MSCs. These alterations could impair the efficacy and limit the therapeutic use of autologous MSCs in subjects with MetS. Our findings may assist in developing adequate regenerative strategies to preserve the reparative potency of MSCs in individuals with MetS. © 2017 International Society for Advancement of Cytometry
Intra‐articular injection of a substance P inhibitor affects gene expression in a joint contracture model
Lewallen, Eric A. , An, Kai‐Nan, Grill, Diane E. , Steinmann, Scott P. , Yao, Jie , Salib, Christopher G. , Trousdale, William H. , Reina, Nicolas , Kremers, Hilal Maradit , Lewallen, David G. , Wijnen, André J. van , Sanchez-Sotelo, Joaquin, Yao, Jie J, Kremers, Hilal M, van Wijnen, Andre J , Morrey, Mark E. , Sánchez‐Sotelo, Joaquín , An, Kai‐Nan , Abdel, Matthew P. , Maradit Kremers, Hilal

Mayo Clinic

Journal of Cellular Biochemistry | July 3, 2017 | Volume: 119 | Issue: 2 | Pages: 1326-1336

10.1002/jcb.26256 | PMID 28671282 Get It

AbstractSubstance P (SP), a neurotransmitter released after injury, has been linked to deregulated tissue repair and fibrosis in musculoskeletal tissues and other organs. Although SP inhibition is an effective treatment for nausea, it has not been previously considered as an anti‐fibrotic therapy. Although there are extensive medical records of individuals who have used SP antagonists, our analysis of human registry data revealed that patients receiving these antagonists and arthroplasty are exceedingly rare, thus precluding a clinical evaluation of their potential effects in the context of arthrofibrosis. Therefore, we pursued in vivo studies to assess the effect of SP inhibition early after injury on pro‐fibrotic gene expression and contractures in an animal model of post‐traumatic joint stiffening. Skeletally mature rabbits (n = 24) underwent surgically induced severe joint contracture, while injected with either fosaprepitant (a selective SP antagonist) or saline (control) early after surgery (3, 6, 12, and 24 h). Biomechanical testing revealed that differences in mean contracture angles between the groups were not statistically significant (P = 0.27), suggesting that the drug neither mitigates nor exacerbates joint contracture. However, microarray gene expression analysis revealed that mRNA levels for proteins related to cell signaling, pro‐angiogenic, pro‐inflammatory, and collagen matrix production were significantly different between control and fosaprepitant treated rabbits (P < 0.05). Hence, our study demonstrates that inhibition of SP alters expression of pro‐fibrotic genes in vivo. This finding will motivate future studies to optimize interventions that target SP to reduce the formation of post‐traumatic joint contractures.
Genetic Breast Cancer Susceptibility Variants and Prognosis in the Prospectively Randomized SUCCESS A Study
Hein, Alexander , Rack, Brigitte , Li, L. , Ekici, Arif B. , Reis, André , Lux, Michael P. , Cunningham, Julie M. , Rübner, Matthias, Schneeweiß, Andreas , Tesch, Hans , Lichtenegger, W., Fehm, Tanja , Heinrich, G. , Rezai, Mahdi , Beckmann, MW, Janni, Wolfgang , Weinshilboum, Richard, Wang, L. , Fasching, PA, Häberle, Lothar , Fridley, Brooke L. , Hein, Alexander , Lux, Michael P , Ekici, Arif B , Reis, André , Fehm, Tanja

Mayo Clinic

Geburtshilfe und Frauenheilkunde | June 28, 2017 | Volume: 77 | Issue: 06 | Pages: 651-659

10.1055/s-0042-113189 | PMID 28757652 Get It

AbstractLarge-scale genotyping studies have identified over 70 single nucleotide polymorphisms (SNPs) associated with breast cancer (BC) risk. However, knowledge regarding genetic risk factors associated with the prognosis is limited. The aim of this study was therefore to investigate the prognostic effect of nine known breast cancer risk SNPs. BC patients (n = 1687) randomly sampled in an adjuvant, randomized phase III trial (SUCCESS A study) were genotyped for nine BC risk SNPs: rs17468277(CASP8), rs2981582(FGFR2), rs13281615(8q24), rs3817198(LSP1), rs889312(MAP3K1), rs3803662(TOX3), rs13387042(2q35), rs4973768(SLC4A7), rs6504950(COX11). Cox proportional hazards models were used to test the SNPsʼ association with overall survival (OS) and progression-free survival (PFS). Additional analyses were carried out for molecular subgroups. rs3817198 in LSP1 (lymphocyte-specific protein 1) was the only SNP that significantly influenced OS (p = 0.01) and PFS (p < 0.01) in the likelihood ratio test comparing the genetic survival model with the clinical survival model. In the molecular subgroups, triple-negative patients with two minor alleles in rs3817198 had a much better prognosis relative to OS (adjusted HR 0.03; 95% CI 0.002 – 0.279) and PFS (HR 0.09; 95% CI 0.02 – 0.36) than patients with the common alleles. The same effect on PFS was shown for patients with luminal A tumors (HR 0.19; 95% CI 0.05 – 0.84), whereas patients with luminal B tumors had a poorer PFS with two minor alleles (HR 2.13; 95% CI 1.02 – 4.40). The variant in rs3817198 has a prognostic effect particularly in the subgroup of patients with triple-negative BC, suggesting a possible link with immunomodulation and BC.
Paucicellular Fibrointimal Proliferation Characterizes Pediatric Pulmonary Vein Stenosis
Kovach, Alexandra E. , Magcalas, Philip M., Ireland, Christina M. , McEnany, Kerry, Oliveira, André M. , Baird, Christopher W. , Vargas, Sara O. , Kieran, Mark W. , Jenkins, Kathy J. , Kovach, Alexandra E

Mayo Clinic

American Journal of Surgical Pathology | June 15, 2017 | Volume: 41 | Issue: 9 | Pages: 1198-1204

10.1097/pas.0000000000000892 | PMID 28622179 Get It

Pulmonary vein stenosis (PVS) is a luminal narrowing of extrapulmonary pulmonary veins. In pediatric patients, it arises following repair of congenital heart disease, particularly anomalous pulmonary venous return; in lung disease, especially prematurity; and rarely in isolation. The etiology is unknown and the course often fatal without lung transplantation. We hypothesized that systematic clinicopathologic review of pediatric PVS could provide further pathogenic insight. We included patients who underwent first resection of pulmonary venous tissue for symptomatic PVS at our pediatric referral center from 1995 to 2014. Clinical records and hematoxylin and eosin slides were reviewed. Subsets were immunostained for smooth muscle actin, Ki-67, β-catenin, estrogen receptor, and other markers and analyzed forUSP6gene rearrangement. A total of 97 patients (57% male; median age: 6 mo) were identified. Overall, 59 (61%) had prior congenital heart disease repair, 35 involving pulmonary vein manipulation. Samples included 213 separate anatomic sites (median: 2/patient). Histologically, all showed sparsely cellular intimal expansion composed of haphazardly arranged fibroblasts with slender nuclei in myxoid matrix. This tissue merged with underlying collagen. Most samples had a variably continuous sheath of cardiomyocytes. Ancillary tests supported a reactive fibroblastic proliferation; in particular, fibroblasts showed cytoplasmic β-catenin localization, no estrogen receptor expression, and noUSP6rearrangement. At last follow-up (mean: 2.3 y), 46% of patients had died of disease. Pediatric PVS uniformly consists of a paucicellular fibrointimal proliferation, irrespective of clinical scenario. It may be best conceived of as a form of reactive hyperplasia. As with other forms of vascular remodeling, trauma (iatrogenic or occult) is likely an inciting factor. A comprehensive understanding of the surgical pathology of PVS may further inform therapeutic strategies in this lethal disease.
Prospective pooled analysis of six phase III trials investigating duration of adjuvant (adjuv) oxaliplatin-based therapy (3 vs 6 months) for patients (pts) with stage III colon cancer (CC): The IDEA (International Duration Evaluation of Adjuvant chemothera
Sobrero, Alberto F. , Shields, Anthony F. , Sougklakos, Ioannis, Bonnetain, Franck, Watanabe, Toshiaki , Boukovinas, Ioannis , Renfro, Lindsay A. , Grothey, Axel, Niedzwiecki, Donna , Shi, Qian , Yoshino, Takayuki , Paul, James , Taı̈eb, Julien , Kerr, Rachel , Labianca, Roberto , Meyerhardt, Jeffrey A. , Torri, Valter , André, Thierry , Sargent, Daniel J. , Iveson, Timothy , Niedzwiecki, Donna

Mayo Clinic

Journal of Clinical Oncology | June 13, 2017 | Volume: 35 | Issue: 18_suppl | Pages: LBA1-LBA1

10.1200/jco.2017.35.18_suppl.lba1 Get It

LBA1 Background: Since 2004, 6 months (m) of oxaliplatin (oxali)-based treatment has been the standard of care as adjuvant therapy for stage III CC. Since oxali is associated with cumulative neurotoxicity, shorter duration of adjuv therapy could spare pts toxicity and lead to substantial saving in health expenditures. Methods: A prospective, pre-planned pooled analysis of 6 concurrently conducted randomized phase III trials (SCOT, TOSCA, Alliance/SWOG 80702, IDEA France (GERCOR/PRODIGE), ACHIEVE, HORG) was performed to evaluate the non-inferiority (NI) of 3m compared with 6m (ref) of adjuv FOLFOX/XELOX. The primary endpoint was disease-free survival (DFS), defined as time from enrolment to relapse, 2nd CRC, and death (all causes). NI was to be declared if the 2-sided 95% confidence interval (CI) for DFS hazard ratio (HR 3m v 6m) estimated by a stratified Cox model was below 1.12. NI was examined within regimen and stage subgroups as pre-planned. Results: The analysis included 12,834 pts from 12 countries, accrued from 6/07 to 12/15. Stage distribution: 13% T1-2, 66% T3, 21% T4; 28% N2; 40% received XELOX. G3+ neurotoxicity was higher in the 6m v 3m arm (16 v 3% FOLFOX, 9 v 3% XELOX, p<0.0001). With a median follow-up of 39 mos, 3263 DFS events were observed. Overall, the 3 year DFS rate was 74.6% (3m) and 75.5% (6m), with estimated DFS HR of 1.07 (95%CI, 1.00-1.15). The 3m v 6m DFS HRs were 1.16 (95%CI, 1.06-1.26) and 0.95 (95% CI, 0.85-1.06) for FOLFOX and XELOX treated pts, respectively. The 3m v 6m DFS HRs were 1.01 (95%CI, 0.90-1.12) in T1-3 N1, and 1.12 (95%CI, 1.03-1.23) for T4 or N2 pts. Conclusions: While NI was not established for the overall cohort, NI of 3m v 6m oxali-based adjuv therapy was supported for XELOX. As each IDEA trial treated varying proportions of pts with XELOX (0 to 75%), the regimen interaction likely produced the differential outcomes observed between individual studies. Certain substages (T1-3 N1) also showed NI for 3m v 6m. These data provide a framework for discussions on risks and benefits of individualized adjuv therapy approaches. Support: U10CA180821, U10CA180882, U10CA180888, U10CA180835, INCA, PHRC2009, EME 09/800/34, HTA 14/140/84, CRUK C1348/A15960, JFMC. Clinical trial information: NCT01150045.
Benefit of Cardiopoietic Mesenchymal Stem Cell Therapy on Left Ventricular Remodelling: Results from the Congestive Heart Failure Cardiopoietic Regenerative Therapy (CHART-1) Study
Metra, Marco , Filippatos, Gerasimos , Povsic, Thomas J. , Henry, Timothy D. , Alexandre, Bertrand, Homsy, Christian, Edwards, Christopher , Seron, Aymeric, Wijns, William , Investigators, for the CHART, Teerlink, John R , Davison, Beth A. , Bartúnek, Jozef , Terzic, André , Gersh, Bernard J. , Cotter, Gad , Investigators, for the CHART, Metra, Marco , Wijns, William

Mayo Clinic

European Journal of Heart Failure | May 31, 2017 | Volume: 19 | Issue: 11 | Pages: 1520-1529

10.1002/ejhf.898 | PMID 28560782 Get It

Abstract Aims Left ventricular (LV) reverse remodelling is an important marker of improved outcomes in patients with advanced heart failure (HF). We examined the impact of the intramyocardial administration of bone-marrow-derived, lineage-directed, autologous cardiopoietic mesenchymal stem cells (C3BS-CQR-1) on LV remodelling in patients with advanced HF enrolled in the CHART-1 study. Methods and results Patients (n=351) with symptomatic advanced HF secondary to ischaemic heart disease, and reduced LV ejection fraction (LVEF &lt;35%) were randomized to receive C3BS-CQR-1 or a sham procedure. In a post hoc analysis we examined the effect of C3BS-CQR-1 on LV reverse remodelling within 1 year of the procedure and the influence of C3BS-CQR-1 dosing in the 271 patients treated as randomized. Delivery of C3BS-CQR-1 was associated with a progressive decrease in both LV end-diastolic volume (LVEDV) and end-systolic volume (LVESV) within 52 weeks after treatment. At 1 year, the LVEDV and LVESV of treated patients decreased by 17.0 mL and 12.8 mL greater than controls (P=0.006 and P=0.017, respectively). The effect on LVEDV was maintained after multivariable adjustment for baseline age, systolic blood pressure, LVEDV, LVEF and history of myocardial infarction. The largest reverse remodelling was evident in the patients receiving a moderate number of injections (&lt;20). Conclusion In CHART-1, intramyocardial administration of cardiopoietic stem cells led to reverse remodelling as evidenced by significant progressive decreases in LVEDV and LVESV through the 52 weeks of follow-up. Further studies are needed to explore the dose response with regard to cell number and injected volume, and reverse remodelling.
A Versatile Protocol for Studying Calvarial Bone Defect Healing in a Mouse Model
Samsonraj, Rebekah M. , Dudakovic, Amel , Zan, Pengfei, Pichurin, Oksana , Cool, Simon M. , Wijnen, André J. van , van Wijnen, Andre J, van Wijnen, Andre J

Mayo Clinic

Tissue Engineering Part C: Methods | May 24, 2017 | Volume: 23 | Issue: 11 | Pages: 686-693

10.1089/ten.tec.2017.0205 | PMID 28537529 Get It

A Combination of a Polycaprolactone Fumarate Scaffold with Polyethylene Terephthalate Sutures for Intra-Articular Ligament Regeneration
Parry, Joshua A. , Wagner, Eric R. , Kok, Peter L., Dadsetan, Mahrokh, Yaszemski, Michael J. , Wijnen, André J. van , van Wijnen, Andre J, Kakar, Sanjeev , van Wijnen, Andre J , Wagner, Eric R

Mayo Clinic

Tissue Engineering Part A | May 20, 2017 | Volume: 24 | Issue: 3-4 | Pages: 245-253

10.1089/ten.tea.2016.0531 | PMID 28530131 Get It